Table 2.

Number of subjects with primary NRTI and NNRTI drug resistance mutations detected at low frequency (≥2% to 20%) in baseline samples by deep sequencing.

	RPV/FTC/TDF RAP N = 24	EFV/FTC/TDF RAP N = 9	Non-RAP Controls N = 118	Total N = 151
No mutations, n (%)	24 (100%)	9 (100%)	108 (91.5%)	141 (93.4%)
Any NRTI-R a or NNRTI-R b n (%)	0	0	10 (8.5%)	10 (6.6%)
Any NRTI-R, n (%)	0	0	3 (2.5%)	3 (2.0%)
Any NNRTI-R, n (%)	0	0	7 (5.9%)	7 (4.6%)

^a Primary nucleoside/nucleotide reverse transcriptase inhibitor resistance (NRTI-R) mutations are M41L, K65N/R, D67N, T69 insertion/deletion, K70E/R, L74V/I, Y115F, Q151M, M184I/V, L210W, T215Y/F, and K219E/Q/N/R in RT; ^b Primary non-nucleoside reverse transcriptase inhibitor resistance (NNRTI-R) mutations are L100I, K101E/P, K103N/S, V106A/M, V108I, E138A/G/K/Q/R, V179L, Y181C/I/V, Y188C/H/L, G190A/E/Q/S, H221Y, P225H, F227C, and M230I/L in RT.